Eligible patients were randomly allocated to receive one of two treatment sequences ( placebo first followed by ivacaftor 150 mg twice daily [ sequence 1 ] or ivacaftor 150 mg twice daily first followed by placebo [ sequence 2 ] ) of 28 days ' treatment in each period , with a 28-day washout between the two treatment periods .